Current scenario of the search for new antifungal agents to treat Candida auris infections: An integrative review

J Mycol Med. 2022 Mar;32(1):101232. doi: 10.1016/j.mycmed.2021.101232. Epub 2021 Dec 1.

Abstract

Candida auris emerges as an important causative agent of fungal infections, with worrisome mortality rates, mainly in immunocompromised individuals. This scenario is worsened by the limited availability of antifungal drugs and the increasing development of resistance to them. Due to the relevance of C. auris infections to public health, several studies aimed to discover new antifungal compounds capable of overcoming this fungus. Nonetheless, these information are decentralized, precluding the understandment of the current status of the search for new anti-C. auris compounds. Thus, this integrative review aimed to summarize information regarding anti-C. auris compounds reported in literature. After using predefined selection criteria, 71 articles were included in this review, and data from a total of 101 substances were extracted. Most of the studies tested synthetic substances, including several azoles. Moreover, drug repurposing emerges as a suitable strategy to discover new anti-C. auris agents. Few studies, however, assessed the mechanism of action and the in vivo antifungal activity of the compounds. Therefore, more studies must be performed to evaluate the usefulness of these substances as anti-C. auris therapies.

Keywords: Antifungal activity; Candida auris; Candidiasis; Drug repurposing; Yeast.

Publication types

  • Review

MeSH terms

  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Azoles / pharmacology
  • Azoles / therapeutic use
  • Candida
  • Candida auris
  • Candidiasis, Invasive* / drug therapy
  • Drug Resistance, Fungal
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents
  • Azoles